financetom
Business
financetom
/
Business
/
Kits Eyecare Q3 Profit Surges on Record Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kits Eyecare Q3 Profit Surges on Record Revenue
Nov 6, 2025 2:20 PM

04:49 PM EST, 11/06/2025 (MT Newswires) -- Kits Eyecare ( KTYCF ) said on Thursday its third-quarter net income surged on strong revenue growth and improved operational efficiencies.

The company said its profit rose to $1.9 million, or $0.06 per share, in the quarter, up from $0.1 million, or nil, a year earlier, and beat the $0.04 estimate compiled by FactSet.

Revenue rose 25.% year over year to a record $52.4 million from $41.9 million, slightly below the $52.7 million consensus.

Kits said it expects fourth-quarter revenue of $52 million to $54 million and adjusted EBITDA margin of 4% to 6%. The company plans to appoint a chief marketing officer in early 2026 to support its long-term growth strategy.

"We're adding new customers at a record pace, expanding margins, and seeing customers in both glasses and contact lenses return at record levels," said chief executive Roger Hardy. "Making eyecare easy has been a lot of fun this quarter as the team delivered exceptional results across the board for customers and shareholders."

Shares of the company closed down $0.57 to $12.61 on Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Construction Partners Closes Asphalt Acquisition, Raises Fiscal 2025 Outlook
Construction Partners Closes Asphalt Acquisition, Raises Fiscal 2025 Outlook
Nov 4, 2024
10:49 AM EST, 11/04/2024 (MT Newswires) -- Construction Partners ( ROAD ) said Monday that it raised its fiscal 2025 outlook after completing the acquisition of Asphalt, which does business as Lone Star Paving. For fiscal 2025, the company said it now expects $2.48 billion to $2.58 billion in revenue, compared with its prior forecast of $2.42 billion to $2.52...
--AstraZeneca Obesity Pill Well-Tolerated in Type-2 Diabetes Patients, Bloomberg Reports
--AstraZeneca Obesity Pill Well-Tolerated in Type-2 Diabetes Patients, Bloomberg Reports
Nov 4, 2024
10:50 AM EST, 11/04/2024 (MT Newswires) -- Price: 71.49, Change: +0.07, Percent Change: +0.10 ...
Crane Completes $40.5 Million Acquisition of Technifab Products
Crane Completes $40.5 Million Acquisition of Technifab Products
Nov 4, 2024
10:46 AM EST, 11/04/2024 (MT Newswires) -- Crane (CR) said Monday it has completed the $40.5 million acquisition of Technifab Products, a vacuum-insulated pipe and valve supplier for cryogenic applications. The acquisition will become part of Crane's Process Flow Technologies segment, expanding its cryogenics offerings in semiconductor, medical, and pharmaceutical markets, the company said. Crane shares rose 1.6% in recent...
Chevron Posts Q3 Beat As 'Uncertainty Around Hess Deal Remains,' Analysts Say
Chevron Posts Q3 Beat As 'Uncertainty Around Hess Deal Remains,' Analysts Say
Nov 4, 2024
Shares of Chevron Corp ( CVX ) continued to rise in early trading on Monday, after the company reported upbeat third-quarter results. The San Ramon, California-based company reported its results amid an exciting earnings season. Here are some key analyst takeaways. Truist Securities analyst Neal Dingmann maintained a Hold rating, while raising the price target from $150 to $155. RBC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved